Successful Launch of Merieux Participations 3, The New Growth Capital Fund of Merieux Equity Partners

Lyon, France (ots/PRNewswire) -

Mérieux Equity Partners, a management company created by Mérieux
Développement, announces the first closing of its third generation
fund, Mérieux Participations 3, focusing on growth capital within
the healthcare and nutrition sectors.

(Logo: https://mma.prnewswire.com/media/750636/Merieux_Equity_Part
ners_Logo.jpg )

Dedicated to partnering with fast-growing companies in the health
and nutrition sectors, Mérieux Participations 3 was launched in July
2018 with a fundraising goal of more than 300 million euros. Only two
months after the commercial authorization by the French Market
Authorities (AMF), a first closing has been completed with an initial
amount of 200 million euros (or 235 million USD). In addition to the
Mérieux family holding, this 3rd generation fund is backed by renown
investors, such as the Dassault Holding (GIMD), Crédit Agricole
Centre-Est, Crédit Agricole Assurances and Compagnie Financière La
Luxembourgeoise, representing more than 60% of the commitments
to-date.

Mérieux Participations 3 will focus on growth equity investments,
in support of small- to mid-cap companies operating within the
healthcare and nutrition sectors and located in Western Europe or
North America. With a typical ticket size ranging from 20 to 40
million euros per company, this new fund will operate MBO / LBO
transactions as well as traditional growth equity deals, targeting
fast growing companies with a clear potential to become market
leaders at a global level.

Mérieux Equity Partners has already completed its first majority
investment into STIplastics Healthcaring. The investment will allow
this fast-growing company, located near Grenoble (France) and
specialized in the development and manufacturing of plastic solutions
for laboratories within the pharmacy and nutrition sectors, to
strengthen its industrial platform and broaden its product offering
over the coming years.

Through Mérieux Participations 3, Mérieux Equity Partners also
intends to broaden its scope of activity into the nutrition sector.
The firm recently took a minority equity position in Biobest, a
Belgian company commercializing a range of integrated biological
control solutions for the pollination and natural crop protection
market. Mérieux Equity Partners will help Biobest become the global
leader in this rapidly growing market segment.

"We are confident about the success of our investment platform,
in response of the growing demand from entrepreneurs for stronger
and more specialized investors, offering tailor-made financing
solutions." said François Valencony, CEO of Mérieux Equity Partners.
"The commitment of prestigious investors to Mérieux Participations
3, alongside the Mérieux family, reflects the growing interest in
our value proposition, both entrepreneurial and sector-specific,
supported by a unique team."

"Investing in tomorrow's medicine and supporting emerging market
leaders internationally, are priorities for Institut Mérieux and
a genuine component of the entrepreneurial approach of our
family". said Alexandre Mérieux, President of Mérieux Développement.
Alongside the creation of Mérieux Equity Partners and with the
support of family holdings that share our long-term vision, we
intend to strengthen our action in areas with major public health
challenges."

About Mérieux Equity Partners - http://www.merieux-partners.com

About Mérieux Développement -
http://www.merieux-developpement.com

Contact communication - Mérieux Equity Partners S.A.S.

EUROPE: Aurélie BOULLERAY - communication@merieux-partners.com

NORTH AMERICA: Alix SIPAHI - communication@merieux-partners.com

ots Originaltext: Mérieux Equity Partners S.A.S.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
+33-478-873-700
North America tel: +1-617-679-8000

Original-Content von: Mérieux Equity Partners S.A.S., übermittelt durch news aktuell